Europe is home to many life sciences companies, so IP regimes throughout the continent’s jurisdictions need to provide cost-effective, speedy and certain litigation environments if patent disputes are to be satisfactorily settled.
LSIPR talks to Thomas Friede and Johannes Heselberger about why Germany fits this mould.
LSIPR: What are the advantages of litigating a life sciences patent in Germany?
Thomas Friede: I believe that the litigation procedure in Germany is an advantage. It is a very streamlined procedure, which is basically an exchange of written briefs—usually two rounds— before an oral hearing. The oral hearing is very condensed and focused. Even in a large case, a hearing would only be four or five hours long. If that is compared to a full trial in the US or the UK, it’s a fraction of the time and therefore it costs less.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
litigation, patent disputes, Germany